1221485-84-2

Upstream product

• 1383443-32-0 2-(2,4-difluorophenylamino)-7-(R-1,2-isopropylidenglycer-3-yl)-10,11-dihydro-dibenzo-[a,d]-cyclohepten-5-one 
• 871502-87-3 4-bromo-2-formylbenzoic acid 
• 1221485-69-3 2-((2,4-difluorophenyl)amino)-7-methoxy-10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-one 
• 4785-56-2 2-formyl-5-methoxy-benzoic acid 
• 1221486-41-4 2-(3-chlorophenethyl)-5-methoxy-benzoic acid 
• 1353948-58-9 2-(3-chlorophenethenyl)-5-methoxy-benzoic acid 
• 1383443-39-7 (R)-2-chloro-7-(2,2-dimethyl-[1,3]dioxolan-4-yl)methoxy-10,11-dihydro-dibenzo[a,d]cyclohepten-5-one 
• 4741-63-3 6-methoxyphthalide 

Relevant academic research and scientific papers

Design, synthesis, and structure–activity relationship study of potent mapk11 inhibitors

Huntington’s disease (HD) is a rare single-gene neurodegenerative disease, which can only be treated symptomatically. Currently, there are no approved drugs for HD on the market. Studies have found that MAPK11 can serve as a potential therapeutic target f

Design, Synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase

Synthesis, biological testing, structure-activity relationships (SARs), and selectivity of novel disubstituted dibenzosuberone derivatives as p38 MAP kinase inhibitors are described. Hydrophilic moieties were introduced at the 7-, 8-, and 9-position of th

DIBENZOCYCLOHEPTATONE DERIVATIVES AND PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS

The present invention relates to compounds of the formula I wherein R1, R2, R3, R4, X and Y have the meanings given in the description. The compounds have an action which is immunomodulating and inhibits or regulates the release of IL-1β and/or TNF-α. The